Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 9,073 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 9,073 shares of Akero Therapeutics stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $37.91, for a total transaction of $343,957.43. Following the completion of the transaction, the insider now directly owns 95,034 shares in the company, valued at approximately $3,602,738.94. This trade represents a 8.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Catriona Yale also recently made the following trade(s):

• On Monday, March 17th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $44.76, for a total value of $447,600.00.
• On Wednesday, March 12th, Catriona Yale sold 614 shares of Akero Therapeutics stock. The shares were sold at an average price of $44.88, for a total transaction of $27,556.32.
• On Tuesday, February 18th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $49.87, for a total value of $498,700.00.

Akero Therapeutics Price Performance

Shares of AKRO traded up $0.04 during mid-day trading on Monday, hitting $37.67. 884,042 shares of the company traded hands, compared to its average volume of 855,465. The business has a 50-day moving average of $43.27 and a 200 day moving average of $36.23. Akero Therapeutics, Inc. has a one year low of $17.86 and a one year high of $58.40. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $3.00 billion, a price-to-earnings ratio of -10.05 and a beta of -0.18.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). As a group, equities analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Akero Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. acquired a new position in Akero Therapeutics in the fourth quarter valued at about $41,000. Sterling Capital Management LLC grew its holdings in shares of Akero Therapeutics by 764.3% in the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock valued at $50,000 after acquiring an additional 1,582 shares in the last quarter. Quarry LP bought a new stake in shares of Akero Therapeutics during the 4th quarter worth approximately $83,000. Summit Investment Advisors Inc. raised its position in Akero Therapeutics by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company's stock worth $197,000 after acquiring an additional 450 shares in the last quarter. Finally, Hsbc Holdings PLC lifted its stake in Akero Therapeutics by 8.5% in the 4th quarter. Hsbc Holdings PLC now owns 7,886 shares of the company's stock valued at $220,000 after purchasing an additional 621 shares during the last quarter.

Analysts Set New Price Targets

Several research firms recently issued reports on AKRO. Morgan Stanley reaffirmed an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. UBS Group boosted their target price on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a research report on Friday, January 31st. Canaccord Genuity Group raised their price objective on Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. HC Wainwright lifted their target price on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Monday, March 3rd. Finally, Citigroup increased their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $76.29.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.